Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive publishing date : 2021 - 06 - 28 save search
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
Published: 2021-06-28 (Crawled : 20:00) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: -0.66%
H: 0.36%
C: -4.15%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.16%
H: 0.3%
C: -0.31%
treatment phase 2 bone phase 2 results results eb613 conference osteoporosis
Medtronic InPen™ Real-World Data and Extended Infusion Set* Pivotal Trial Results Demonstrate Strong Clinical Outcomes and Positive User Experience
Published: 2021-06-28 (Crawled : 17:00) - biospace.com/
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: 0.29%
H: 0.1%
C: -1.24%
positive trial trial results
Eiger BioPharmaceuticals Announces Presentation of Positive Phase 2 Results of Avexitide in Congenital Hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session
Published: 2021-06-28 (Crawled : 16:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: 4.84%
H: 5.28%
C: -1.65%
presentation diabetes phase 2 biopharma positive phase 2 results results insulin
MYM’s Acquisition by IMCC Receives Positive Recommendations from leading Independent Proxy Advisory Firms
Published: 2021-06-28 (Crawled : 14:00) - globenewswire.com
IMCC | $0.611 -15.93% -18.95% 600K
|
Manufacturing
|
| O: 2.56%
H: 3.27%
C: 3.27%
acquisition positive
Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1
Published: 2021-06-28 (Crawled : 12:15) - globenewswire.com
DARE | $0.2838 -3.83% -3.98% 550K
|
Health Technology
|
| O: 0.0%
H: 1.78%
C: -0.59%
phase 1 positive results phase 2 phase 3 bioscience
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
Published: 2021-06-28 (Crawled : 12:00) - ir.hoththerapeutics.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 1.26%
H: 4.97%
C: -1.86%
treatment phase 1 positive results dermatitis trial atopic dermatitis phase 1b al001 adi-001 phase 2b
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
Published: 2021-06-28 (Crawled : 10:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.34%
H: 0.47%
C: 0.24%
KYMR | $33.965 -3.29% -3.4% 630K
|
Health Technology
|
| O: 2.97%
H: 3.46%
C: 3.24%
phase 1 positive results trial phase 2
Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
Published: 2021-06-28 (Crawled : 08:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.34%
H: 0.47%
C: 0.24%
phase 2 phase 2/3 positive results topline trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
SIX | $23.45 -0.55% 0.68% 650K
|
Consumer Services
KNSL 4 | $451.81 -0.02% 0.49% 140K
|
Finance
SENS | $0.3992 -4.04% 0.45% 2M
|
Electronic Technology
BSBR | $5.25 2.54% 0.38% 430K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.